# name
Combating poor-quality anti-malarial medicines: a call to action

# metadata.dc.description.abstract[].value
The circulation of poor-quality medicines continues to undermine
                the fight against many life-threatening diseases. Anti-malarial
                medicines appear to have been particularly compromised and
                present a major public health threat in malaria-endemic
                countries, negatively affecting individuals and their
                communities. Concerted collaborative efforts are required from
                global, regional and national organizations, involving the
                public and private sectors, to address the problem. While many
                initiatives are underway, a number of unmet needs deserve urgent
                and increased multisector attention. At the global level, there
                is a need for an international public health legal framework or
                treaty on poor-quality medicines, with statutes suitable for
                integration into national laws. In addition, increased
                international efforts are required to strengthen the governance
                of global supply chains and enhance cooperation between national
                medicine regulation authorities and law enforcement bodies.
                Increased investment is needed in innovative technologies that
                will enable healthcare teams to detect poor-quality medicines at
                all levels of the supply chain. At the regional level, a number
                of initiatives would be beneficial-key areas are
                standardization, simplification, and reciprocal recognition of
                registration processes and development of quality control
                capacity in regional centres of excellence that are better
                aligned with public health needs; improved surveillance methods
                and creation of a framework for compulsory and transparent
                reporting of poor-quality medicines; additional support for
                national medicine regulation authorities and other national
                partner authorities; and an increase in support for regional
                laboratories to boost their capabilities in detecting
                poor-quality medicines. It is vital that all stakeholders
                involved in efforts against poor-quality anti-malarial medicines
                extend and strengthen their actions in these critical areas and
                thus effectively support global health development and malaria
                elimination programmes.

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
Combating poor-quality anti-malarial medicines: a call to action